Cancer Risk after Cyclophosphamide Treatment in Idiopathic Membranous Nephropathy | Zendy

Jan A.J.G. van den Brand | Zendy; Peter R. van Dijk | Zendy; Julia M. Hofstra | Zendy; Jack F.M. Wetzels | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cancer Risk after Cyclophosphamide Treatment in Idiopathic Membranous Nephropathy

Author(s) -

Jan A.J.G. van den Brand,

Peter R. van Dijk,

Julia M. Hofstra,

Jack F.M. Wetzels

Publication year - 2014

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.08880813

Subject(s) - medicine , cyclophosphamide , membranous nephropathy , nephropathy , cancer , oncology , dermatology , glomerulonephritis , chemotherapy , endocrinology , kidney , diabetes mellitus

Cyclophosphamide treatment improves renal survival in patients with idiopathic membranous nephropathy. However, use of cyclophosphamide is associated with cancer. The incidence of malignancies in patients with idiopathic membranous nephropathy was evaluated, and the cancer risk associated with cyclophosphamide use was estimated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research